ACT Capital Management LLC Takes $14.92 Million Position in Krystal Biotech, Inc. $KRYS

ACT Capital Management LLC bought a new stake in Krystal Biotech, Inc. (NASDAQ:KRYS) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 60,500 shares of the company’s stock, valued at approximately $14,916,000. Krystal Biotech makes up approximately 12.1% of ACT Capital Management LLC’s portfolio, making the stock its largest position.

Several other institutional investors also recently modified their holdings of the business. Sound Income Strategies LLC grew its holdings in Krystal Biotech by 1,270.0% during the fourth quarter. Sound Income Strategies LLC now owns 137 shares of the company’s stock valued at $34,000 after purchasing an additional 127 shares during the period. Greenline Wealth Management LLC bought a new position in Krystal Biotech during the fourth quarter valued at $34,000. Danske Bank A S bought a new position in Krystal Biotech during the third quarter valued at $35,000. UMB Bank n.a. grew its holdings in Krystal Biotech by 34.6% during the fourth quarter. UMB Bank n.a. now owns 144 shares of the company’s stock valued at $36,000 after purchasing an additional 37 shares during the period. Finally, Global Retirement Partners LLC grew its holdings in Krystal Biotech by 788.9% during the fourth quarter. Global Retirement Partners LLC now owns 160 shares of the company’s stock valued at $39,000 after purchasing an additional 142 shares during the period. 86.29% of the stock is owned by institutional investors.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $341.66 on Thursday. The company has a market cap of $10.07 billion, a P/E ratio of 45.68 and a beta of 0.53. The stock’s fifty day moving average price is $292.56 and its two-hundred day moving average price is $270.63. Krystal Biotech, Inc. has a 1 year low of $127.99 and a 1 year high of $347.67.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, May 4th. The company reported $1.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.45 by $0.38. Krystal Biotech had a return on equity of 19.25% and a net margin of 53.92%.The firm had revenue of $116.36 million for the quarter, compared to the consensus estimate of $112.11 million. On average, analysts expect that Krystal Biotech, Inc. will post 7.83 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, EVP John Charles Thomas sold 642 shares of the stock in a transaction on Tuesday, May 26th. The stock was sold at an average price of $302.03, for a total value of $193,903.26. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Suma Krishnan sold 25,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $308.11, for a total value of $7,702,750.00. Following the completion of the sale, the insider owned 1,378,155 shares in the company, valued at $424,623,337.05. This trade represents a 1.78% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Company insiders own 13.10% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on KRYS. HC Wainwright increased their price objective on Krystal Biotech from $310.00 to $361.00 and gave the company a “buy” rating in a report on Tuesday. Guggenheim increased their price objective on Krystal Biotech from $224.00 to $284.00 and gave the company a “buy” rating in a report on Wednesday, February 25th. Citigroup increased their target price on Krystal Biotech from $371.00 to $378.00 and gave the stock a “buy” rating in a research report on Tuesday, May 5th. Evercore restated an “outperform” rating and set a $300.00 target price on shares of Krystal Biotech in a research report on Tuesday, May 5th. Finally, Wall Street Zen upgraded Krystal Biotech from a “hold” rating to a “buy” rating in a research report on Saturday, May 9th. Ten research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $329.78.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.